Everand Logo

Welcome to Everand!

  • STAT

    LISTEN: Pharma at the ballot box, the latest Alzheimer’s argument, and truly personalized medicine

    Can a donut hole get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really? Find out on our biotech…
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Oct 25, 2018 1 minute

    Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does “positive” even mean, really?

    We discuss all

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks